Avinger, Inc. is a medical device company headquartered in Redwood City, California, that specializes in the development and commercialization of image-guided, catheter-based systems for the diagnosis and treatment of peripheral artery disease (PAD). Its proprietary technology platform integrates high-resolution intravascular imaging with precision atherectomy to enable clinicians to visualize and remove plaque build-up in peripheral vessels. The company’s products are designed to enhance safety and efficacy in minimally invasive vascular procedures, offering an alternative to traditional approaches that rely solely on fluoroscopy or balloon angioplasty.
The company’s flagship devices include the Ocelot™ and Pantheris™ families. The Ocelot system utilizes optical coherence tomography (OCT) to provide real-time intraluminal images, allowing clinicians to safely cross chronic total occlusions. The Pantheris platform combines OCT imaging with directional atherectomy, enabling targeted plaque excision while preserving healthy tissue. Avinger continues to advance its pipeline with additional catheter sizes and indications, reinforcing its position in the rapidly growing PAD market.
Founded in 2007 under the name Parkview Medical, Inc., the company rebranded as Avinger in 2012 to reflect its focus on cutting-edge vascular technologies. Since receiving FDA clearance for its first OCT-guided device in 2016, Avinger has expanded its commercial footprint across the United States and established partnerships in Europe, Latin America and select Asia-Pacific regions. The company maintains a network of direct sales professionals and distributors to support adoption among interventional cardiologists, radiologists and vascular surgeons.
Avinger’s leadership team is led by President and Chief Executive Officer Scott R. Ward, who has guided the company through regulatory milestones and commercialization efforts. Backed by a board of directors and medical advisory councils composed of seasoned industry executives and vascular specialists, Avinger is positioned to pursue ongoing innovation in the treatment of peripheral artery disease and related vascular disorders.
AI Generated. May Contain Errors.
